thiophenes has been researched along with Fatty Liver, Nonalcoholic in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (65.22) | 24.3611 |
| 2020's | 8 (34.78) | 2.80 |
| Authors | Studies |
|---|---|
| Aishima, S; Anzai, K; Eguchi, Y; Fujii, H; Hyogo, H; Imajo, K; Isoda, H; Kage, M; Kawaguchi, A; Kawanaka, M; Kessoku, T; Kitajima, Y; Kubotsu, Y; Kurai, O; Nakajima, A; Nakajima, T; Nonaka, M; Oeda, S; Ono, M; Tajiri, R; Takahashi, H; Takamori, A; Tanaka, K; Yoneda, M | 1 |
| Fujihara, S; Fujita, K; Haba, R; Himoto, T; Iwama, H; Masaki, T; Morishita, A; Nakahara, M; Nishiyama, A; Okano, K; Ono, M; Oura, K; Shi, T; Tadokoro, T; Takuma, K; Tani, J | 1 |
| Anzai, K; Takahashi, H | 1 |
| de Knegt, RJ; van Kleef, LA | 1 |
| Fan, YS; Huang, YW; Ke, YY; Lee, JC; Lin, CY; Rajan, YC; Shen, ZQ; Shiao, HY; Song, JS; Tsai, CH; Tsai, TF; Yao, CH; Yeh, TK | 1 |
| Tahara, A; Takasu, T | 1 |
| Fukuda, S; Hosokawa, K; Ida, A; Isomoto, H; Iyama, T; Kanda, T; Koda, M; Mae, Y; Matono, T; Sugihara, T; Takata, T; Taniguchi, S; Yamamoto, M | 1 |
| Bedia-Diaz, G; Burris, TP; Elgendy, B; Griffett, K | 1 |
| Fu, Z; Hu, L; Ma, L; Ni, L; Ni, Y; Wang, Z; Zhao, Y | 1 |
| Tahara, A | 1 |
| Lin, J; Wang, SY | 1 |
| Kim, W; Kim, YJ | 1 |
| Hayashi, M; Hirokawa, F; Jin, D; Komeda, K; Masubuchi, S; Miyaoka, Y; Takai, S; Tashiro, K; Uchiyama, K | 1 |
| Akiyama, Y; Inoue, K; Inukai, K; Ito, D; Morimoto, Y; Noda, M; Saito, D; Shimada, A; Shimizu, S; Yanagisawa, M | 1 |
| Fujimori, T; Ichikawa, K; Irahara, A; Kimata, K; Koketsu, Y; Nakano, A; Senda, E; Sumida, Y; Takata, E; Takeda, A; Yamada, H | 1 |
| Bailly-Maitre, B; Chevet, E; Hazari, Y; Hetz, C; Lebeaupin, C; Vallée, D | 1 |
| Maegawa, H; Nakamura, I; Tabuchi, H; Tobe, K; Uno, S | 1 |
| Hayashizaki-Someya, Y; Koide, K; Kurosaki, E; Mitori, H; Takakura, S; Takasu, T; Yamazaki, S | 1 |
| Fujita, K; Honda, Y; Imajo, K; Kato, S; Kato, T; Kessoku, T; Mawatari, H; Nakajima, A; Ogawa, Y; Saito, S; Tomeno, W; Yoneda, M | 1 |
| Isogawa, A; Ohki, T; Tagawa, K; Toda, N | 1 |
| Furuke, S; Kanno, K; Komiya, C; Miyachi, Y; Ogawa, Y; Shiba, K; Shimazu, N; Tsuchiya, K; Yamaguchi, S | 1 |
| Atsumi, T; Miyoshi, H; Nakamura, A; Takase, T; Yamamoto, C | 1 |
| Chang, MS; Cho, JY; Kim, BG; Kim, H; Kim, JH; Kim, SG; Kim, W; Kim, YJ; Lee, CK; Lee, J; Lee, JH; Lee, JS; Yeon, JE; Yi, S | 1 |
1 review(s) available for thiophenes and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease.
Topics: Activating Transcription Factor 6; Animals; Autophagy; Calcium; Endoplasmic Reticulum Stress; Genetic Therapy; Humans; Insulin Resistance; Lipid Metabolism; Non-alcoholic Fatty Liver Disease; Signal Transduction; Sulfonamides; Thiophenes; Unfolded Protein Response | 2018 |
3 trial(s) available for thiophenes and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2022 |
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
Topics: Adult; Animals; Double-Blind Method; Fatty Liver; Female; Humans; Liver X Receptors; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Mice; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes; Treatment Outcome; Ultrasonography | 2017 |
19 other study(ies) available for thiophenes and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Fasting; Gene Expression Profiling; Gene Expression Regulation; Glucosides; Hepatocytes; Hypoglycemic Agents; Interleukin-1beta; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Non-alcoholic Fatty Liver Disease; Signal Transduction; Streptozocin; Superoxide Dismutase; Thiophenes; Tumor Necrosis Factor-alpha | 2022 |
Reply to the Letter to the editor "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".
Topics: Diabetes Mellitus; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Thiophenes | 2022 |
Reply to: "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".
Topics: Diabetes Mellitus; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Thiophenes | 2022 |
Discovery of tetrasubstituted thiophenes as Cisd2 activators: A potential novel therapeutic option in nonalcoholic fatty liver disease.
Topics: Animals; Down-Regulation; Hepatocytes; Liver; Mice; Non-alcoholic Fatty Liver Disease; Thiophenes | 2023 |
SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Progression; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rodentia; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules.
Topics: Animals; Apoptosis; Disease Models, Animal; Down-Regulation; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glucosides; Heat-Shock Proteins; Male; Mice; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Thiophenes; Transcription Factor CHOP; Triglycerides | 2019 |
REV-ERB agonism improves liver pathology in a mouse model of NASH.
Topics: Animals; Disease Models, Animal; Humans; Inflammation; Lipogenesis; Liver; Liver Cirrhosis; Mice; Non-alcoholic Fatty Liver Disease; Nuclear Receptor Subfamily 1, Group D, Member 1; Obesity; Pyrrolidines; Thiophenes | 2020 |
Pharmacological activation of REV-ERBα improves nonalcoholic steatohepatitis by regulating intestinal permeability.
Topics: Animals; Autophagy; Blood Glucose; Caco-2 Cells; Cholesterol; Humans; Insulin; Intestinal Mucosa; Intestines; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Permeability; Pyrrolidines; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Signal Transduction; Thiophenes; Tight Junctions; Triglycerides | 2021 |
Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
Topics: Animals; Aquaporin 2; Body Fluids; Diabetes Mellitus, Type 2; Diuresis; Drinking; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Organ Size; Osmolar Concentration; Pioglitazone; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed.
Topics: Fatty Liver; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes | 2017 |
Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed-authors' reply.
Topics: Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes | 2017 |
Chymase inhibitor prevents the development and progression of non-alcoholic steatohepatitis in rats fed a high-fat and high-cholesterol diet.
Topics: Animals; Cholesterol, Dietary; Chymases; Diet, High-Fat; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Male; Non-alcoholic Fatty Liver Disease; Rats, Inbred SHR; Sulfonamides; Thiophenes | 2017 |
The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin.
Topics: Aged; Alanine Transaminase; Diabetes Mellitus, Type 2; Female; Ferritins; Glucosides; Humans; Hypoglycemic Agents; Liver Function Tests; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2; Thiophenes | 2017 |
Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results).
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Asian People; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Humans; Japan; Liver; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Product Surveillance, Postmarketing; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
Topics: Amino Acids; Animals; Choline Deficiency; Food, Formulated; Glucosides; Hydroxyproline; Hypoglycemic Agents; Inflammation; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rats; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Thiophenes; Triglycerides | 2015 |
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hypoglycemic Agents; Insulin Resistance; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2016 |
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Pep
Topics: Alanine Transaminase; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucosides; Humans; Incretins; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Topics: Adipose Tissue; Adult; Animals; Body Weight; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Epididymis; Glucose; Glucosides; Humans; Hyperphagia; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.
Topics: Adiposity; Adult; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Japan; Lipotropic Agents; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Severity of Illness Index; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |